SKYE

SEC source: 0001516551-23-000014 · wf-form4a_167328166436192.xml · derivative · entry 1

TYLE PRAVEEN · CIK 0001296936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2033-01-05

F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.017 per option share for ten years from January 5, 2023 (the "Grant Date") and the options will vest in equal monthly installments over the one year period from December 8, 2022.

SEC source: 0001516551-23-000012 · wf-form4_167328138631481.xml · derivative · entry 1

DALESANDRO MARGARET · CIK 0001208853 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2033-01-05

F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.017 per option share for ten years from January 5, 2023 and the options will vest in equal monthly installments over the one year period beginning December 8, 2022.

SEC source: 0001516551-23-000010 · wf-form4_167327894567784.xml · derivative · entry 1

Ward Keith Wayne · CIK 0001662394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2033-01-05

F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.017 per option share for ten years from January 5, 2023 and the options will vest in equal monthly installments over the one year period beginning December 8, 2022.

SEC source: 0001516551-23-000008 · wf-form4_167327820816124.xml · derivative · entry 1

Rai Sukhwinder Singh · CIK 0001947352 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2033-01-05

F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.017 per option share for ten years from January 5, 2023 and the options will vest in equal monthly installments over the one year period beginning November 10, 2022.

SEC source: 0001516551-22-000047 · wf-form4_166853764730845.xml · derivative · entry 6

DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 292,500

Underlying: Common Stock · 292,500 shares

Expires 2025-08-03

F3 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio.

F3 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio.

F6 · derivative.exercise_date: 8.33% of the options vested on the grant date of August 3, 2020. An additional 8.333% of the options vest on each monthly anniversary of the grant date.

SEC source: 0001516551-22-000047 · wf-form4_166853764730845.xml · derivative · entry 5

DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 487,500

Underlying: Common Stock · 487,500 shares

Expires 2025-04-27

F3 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio.

F3 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio.

F4 · derivative.exercise_date: The options underlying this award are fully vested.

SEC source: 0001516551-22-000047 · wf-form4_166853764730845.xml · derivative · entry 4

DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 390,000

Underlying: Common Stock · 390,000 shares

Expires 2025-02-06

F3 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio.

F3 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio.

F5 · derivative.exercise_date: Options will vest, or have vested, in equal installments on each of February 6, 2020, February 6, 2021, February 6, 2022, February 6, 2023.

SEC source: 0001516551-22-000047 · wf-form4_166853764730845.xml · derivative · entry 3

DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 390,000

Underlying: Common Stock · 390,000 shares

Expires 2024-04-03

F3 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio.

F3 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio.

F4 · derivative.exercise_date: The options underlying this award are fully vested.

SEC source: 0001516551-22-000047 · wf-form4_166853764730845.xml · nonDerivative · entry 2

DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust

Disclosed balance after: 2,335,721

F1 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement, dated as of May 11, 2022 (as amended, the "Arrangement Agreement"). Pursuant to the terms of the Arrangement Agreement, each holder of EHT shares received 1.95 shares of company common stock for each EHT share (the "Exchange Ratio").

F1 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement, dated as of May 11, 2022 (as amended, the "Arrangement Agreement"). Pursuant to the terms of the Arrangement Agreement, each holder of EHT shares received 1.95 shares of company common stock for each EHT share (the "Exchange Ratio").

F2 · ownership.nature: The shares are held by a trust for which the Reporting Person is a trustee and has voting and dispositive power over the shares.

SEC source: 0001516551-22-000047 · wf-form4_166853764730845.xml · nonDerivative · entry 1

DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,406,543

F1 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement, dated as of May 11, 2022 (as amended, the "Arrangement Agreement"). Pursuant to the terms of the Arrangement Agreement, each holder of EHT shares received 1.95 shares of company common stock for each EHT share (the "Exchange Ratio").

F1 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement, dated as of May 11, 2022 (as amended, the "Arrangement Agreement"). Pursuant to the terms of the Arrangement Agreement, each holder of EHT shares received 1.95 shares of company common stock for each EHT share (the "Exchange Ratio").

SEC source: 0001516551-22-000045 · wf-form4_166853302798842.xml · derivative · entry 6

Rai Sukhwinder Singh · CIK 0001947352 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 195,000

Underlying: Common Stock · 195,000 shares

Expires 2025-08-03

F4 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio.

F4 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio.

F7 · derivative.exercise_date: 8.33% of the options vested on the grant date of August 3, 2020. 8.33% of the options vest, or have vested, on each monthly anniversary of the grant date.

SEC source: 0001516551-22-000045 · wf-form4_166853302798842.xml · derivative · entry 5

Rai Sukhwinder Singh · CIK 0001947352 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,250

Underlying: Common Stock · 146,250 shares

Expires 2025-02-06

F4 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio.

F4 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio.

F6 · derivative.exercise_date: The options vest, or have vested, in equal installments on each of February 6, 2020, February 6, 2021, February 6, 2022, February 6, 2023.

SEC source: 0001516551-22-000045 · wf-form4_166853302798842.xml · derivative · entry 4

Rai Sukhwinder Singh · CIK 0001947352 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,250

Underlying: Common Stock · 146,250 shares

Expires 2022-12-22

F4 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio.

F4 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio.

F5 · derivative.exercise_date: The options underlying this award are fully vested.

SEC source: 0001516551-22-000045 · wf-form4_166853302798842.xml · derivative · entry 3

Rai Sukhwinder Singh · CIK 0001947352 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 390,000

Underlying: Common Stock · 390,000 shares

Expires 2024-04-02

F4 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio.

F4 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio.

F5 · derivative.exercise_date: The options underlying this award are fully vested.

SEC source: 0001516551-22-000045 · wf-form4_166853302798842.xml · nonDerivative · entry 2

Rai Sukhwinder Singh · CIK 0001947352 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares held by wife of Reporting Person

Disclosed balance after: 73,561

F1 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement, dated as of May 11, 2022 (as amended, the "Arrangement Agreement"). Pursuant to the terms of the Arrangement Agreement, each holder of EHT shares received 1.95 shares of company common stock for each EHT share (the "Exchange Ratio").

F1 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement, dated as of May 11, 2022 (as amended, the "Arrangement Agreement"). Pursuant to the terms of the Arrangement Agreement, each holder of EHT shares received 1.95 shares of company common stock for each EHT share (the "Exchange Ratio").

F3 · balance_after: For each indirect account, Mr. Rai disclaims beneficial ownership except to the extent of his pecuniary interest, if any.

SEC source: 0001516551-22-000045 · wf-form4_166853302798842.xml · nonDerivative · entry 1

Rai Sukhwinder Singh · CIK 0001947352 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust

Disclosed balance after: 22,157

F1 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement, dated as of May 11, 2022 (as amended, the "Arrangement Agreement"). Pursuant to the terms of the Arrangement Agreement, each holder of EHT shares received 1.95 shares of company common stock for each EHT share (the "Exchange Ratio").

F1 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement, dated as of May 11, 2022 (as amended, the "Arrangement Agreement"). Pursuant to the terms of the Arrangement Agreement, each holder of EHT shares received 1.95 shares of company common stock for each EHT share (the "Exchange Ratio").

F2 · ownership.nature: The shares are held through the Canaccord Genuity Trust.

SEC source: 0001567619-23-005234 · doc1.xml · derivative · entry 3

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,141,486

Underlying: Common Stock · 9,141,486 shares

Expires 2024-12-30

F1 · kind: Warrants were acquired pursuant to a merger between Issuer and Emerald Health Therapeutics, Inc. ("Emerald"), whereby Reporting Person's outstanding warrants to purchase Emerald common stock were exchanged for warrants to purchase Issuer common stock.

SEC source: 0001516551-21-000027 · wf-form4_163969915831608.xml · derivative · entry 2

Arsenault Kaitlyn Melanie · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,770,000

Underlying: Common Stock · 1,770,000 shares

Expires 2031-12-14

F3 · derivative.exercise_date: The option vests 25% on the one year anniversary of the grant date and 1/48th monthly thereafter. Upon a change in control of the Issuer, 100% of the options will become fully vested.

SEC source: 0001516551-21-000027 · wf-form4_163969915831608.xml · nonDerivative · entry 1

Arsenault Kaitlyn Melanie · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000,000

F1 · shares: Represents a restricted stock unit ("RSU") award that vests in three equal annual installments commencing on the first anniversary of the grant date. Upon a change in control of the Issuer, all of the RSUs will vest in full.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001516551-21-000029 · wf-form4_163969937662511.xml · derivative · entry 2

DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,090,000

Underlying: Common Stock · 3,090,000 shares

Expires 2031-12-14

F3 · derivative.exercise_date: The option vests 25% on the one year anniversary of the grant date and 1/48th monthly thereafter. Upon a change in control of the Issuer, 100% of the options will become fully vested.

SEC source: 0001516551-21-000029 · wf-form4_163969937662511.xml · nonDerivative · entry 1

DHILLON PUNIT · CIK 0001425052 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000,000

F1 · shares: Represents a restricted stock unit ("RSU") award that vests in three equal annual installments commencing on the first anniversary of the grant date. Upon a change in control of the Issuer, all of the RSUs will vest in full.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001516551-21-000025 · wf-form4_163969862196316.xml · derivative · entry 1

Ward Keith Wayne · CIK 0001662394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2031-12-14

F1 · derivative.exercise_date: The Option grant shall be exercisable for a price of $0.058 per Option Share for ten years from December 14, 2021 (the "Grant Date") and the Options will vest in equal monthly installments over the one year period from the Grant Date.

SEC source: 0001516551-21-000014 · wf-form4_163348095684882.xml · derivative · entry 1

Arsenault Kaitlyn Melanie · CIK 0001877242 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000,000

Underlying: Common Stock · 1,600,000 shares

Expires 2031-10-04

F1 · derivative.exercise_date: 10% of the Options shall vest on October 4, 2021 (the "Vesting Start Date") and the remaining 90% of the Options will vest in equal semi-annual installments over four annual periods.

SEC source: 0001628280-21-018754 · wf-form4_163182245212535.xml · derivative · entry 1

TYLE PRAVEEN · CIK 0001296936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 275,000

Underlying: Common Stock · 25,000 shares

Expires 2031-09-14

F1 · derivative.exercise_date: The Option shall be exercisable for a price of $0.12 per Option Share in twelve equal monthly installments such that all the Option Shares shall vest in twelve months.

SEC source: 0001628280-21-018755 · wf-form4_163182251103569.xml · derivative · entry 1

HEPPELL JAMES L · CIK 0001261140 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,350,000

Underlying: Common Stock · 150,000 shares

Expires 2031-09-14

F1 · derivative.exercise_date: The Option shall be exercisable for a price of $0.12 per Option Share in twelve equal monthly installments such that all the Option Shares shall vest in twelve months.

SEC source: 0001628280-21-018756 · wf-form4_163182260221131.xml · derivative · entry 1

DALESANDRO MARGARET · CIK 0001208853 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 150,000 shares

Expires 2031-09-14

F1 · derivative.exercise_date: The Option shall be exercisable for a price of $0.12 per Option Share in twelve equal monthly installments such that all the Option Shares shall vest in twelve months.

SEC source: 0001140361-21-025590 · form4.xml · derivative · entry 1

TYLE PRAVEEN · CIK 0001296936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2031-07-22

F1 · derivative.exercise_date: Each of the Options shall be exercisable for a price of $0.14 per Option Share for ten years from July 22, 2021 (the "Grant Date") and all Options will vest 10% on the Grant Date and 90% in equal semiannual installments over two years.

SEC source: 0001640334-20-002024 · form4.xml · derivative · entry 1

Traistaru Elena · CIK 0001811125 · CFO and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000,000

Underlying: Common Stock · 1,000,000 shares

Expires 2030-08-07

F1 · derivative.exercise_date: Each of the Options shall be exercisable for a price of $0.045 per Option Share for ten years from August 7, 2020 (the "Grant Date") and all Options will vest 10% on the Grant Date and 90% in equal semiannual installments over four years.

SEC source: 0001640334-20-002025 · form4.xml · derivative · entry 1

KIM DENNIS D · CIK 0001456750 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,736,541

Underlying: Common Stock · 4,000,000 shares

Expires 2030-08-07

F1 · derivative.exercise_date: Each of the Options shall be exercisable for a price of $0.045 per Option Share for ten years from August 7, 2020 (the "Grant Date") and all Options will vest 10% on the Grant Date and 90% in equal semiannual installments over four years.

SEC source: 0001640334-20-002027 · form4.xml · derivative · entry 2

DHILLON PUNIT · CIK 0001425052 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,200,000

Underlying: Common Stock · 9,000,000 shares

Expires 2030-08-07

F2 · derivative.exercise_date: Each of the Options shall be exercisable for a price of $0.045 per Option Share for ten years from August 7, 2020 (the "Grant Date") and all Options will vest 10% on the Grant Date and 90% in equal semiannual installments over four and a half years.

SEC source: 0001640334-20-002027 · form4.xml · nonDerivative · entry 1

DHILLON PUNIT · CIK 0001425052 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000,000

F1 · price: Private purchase transaction from Emerald Health Sciences at $0.10 per share.

SEC source: 0001640334-20-002026 · form4.xml · derivative · entry 2

HEPPELL JAMES L · CIK 0001261140 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,200,000

Underlying: Common Stock · 1,000,000 shares

Expires 2030-08-07

F2 · derivative.exercise_date: Each of the Options shall be exercisable for a price of $0.045 per Option Share for ten years from August 7, 2020 (the "Grant Date") and all Options will vest 10% on the Grant Date and 90% in equal semiannual installments over two years.

SEC source: 0001640334-20-002026 · form4.xml · nonDerivative · entry 1

HEPPELL JAMES L · CIK 0001261140 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

F1 · price: Private purchase transaction from Emerald Health Sciences at $0.10 per share.

SEC source: 0001640334-20-002029 · form4.xml · nonDerivative · entry 1

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,490,167

F1 · shares: Transfer of shares in a private transaction to directors, employees and consultants.

SEC source: 0001640334-20-002044 · primary_doc.xml · derivative · entry 1

DALESANDRO MARGARET · CIK 0001208853 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2030-08-07

F1 · derivative.exercise_date: Each of the Options shall be exercisable for a price of $0.045 per Option Share for ten years from August 7, 2020 (the "Grant Date") and all Options will vest 10% on the Grant Date and 90% in equal semiannual installments over two years.

SEC source: 0001640334-20-002100 · form4a.xml · nonDerivative · entry 1

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,923,501

F1 · shares: The original Form 4, filed on August 11, 2020, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported a sale that occurred on August 7, 2020, as a total of 3,000,000 shares sold when in fact 2,566,6660 shares of the Issuer's common stock were sold. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects an addition in the number of shares reported as beneficially owned by the reporting person by 433,334 shares.

F1 · balance_after: The original Form 4, filed on August 11, 2020, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported a sale that occurred on August 7, 2020, as a total of 3,000,000 shares sold when in fact 2,566,6660 shares of the Issuer's common stock were sold. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects an addition in the number of shares reported as beneficially owned by the reporting person by 433,334 shares.

SEC source: 0001640334-22-000206 · form5.xml · nonDerivative · entry 1

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,387,251

F1 · kind: Transactions were previously reported on various prior Form 4 filings; however, the entries were erroneously reported as non-derivative transactions in Common Stock and the resulting reported total ownership included the misclassified securities. The entry of these transactions is to correct this error and reflect the actual securities held by the Reporting Person.

SEC source: 0001640334-22-000206 · form5.xml · derivative · entry 6

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,354,861

Underlying: Common Stock · 5,354,861 shares

Expires 2022-10-05

F1 · kind: Transactions were previously reported on various prior Form 4 filings; however, the entries were erroneously reported as non-derivative transactions in Common Stock and the resulting reported total ownership included the misclassified securities. The entry of these transactions is to correct this error and reflect the actual securities held by the Reporting Person.

F2 · derivative.expiration_date: The Multi Draw Credit Facility tranches have the option to convert into Common Stock upon maturity of the facilities.

SEC source: 0001640334-22-000206 · form5.xml · derivative · entry 4

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500,000

Underlying: Common Stock · 2,500,000 shares

Expires 2024-03-29

F1 · kind: Transactions were previously reported on various prior Form 4 filings; however, the entries were erroneously reported as non-derivative transactions in Common Stock and the resulting reported total ownership included the misclassified securities. The entry of these transactions is to correct this error and reflect the actual securities held by the Reporting Person.

SEC source: 0001209191-19-006473 · doc4.xml · derivative · entry 2

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500,000

Underlying: Common Stock · 2,500,000 shares

Expires not disclosed

F2 · kind: The common stock purchase warrant (the "Warrant") was issued to the reporting person in connection with the Advance pursuant to the Agreement. The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance.

F3 · shares: Represents 50% of the number of shares issuable upon conversion of the Advance.

F2 · price: The common stock purchase warrant (the "Warrant") was issued to the reporting person in connection with the Advance pursuant to the Agreement. The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance.

F2 · derivative.exercise_date: The common stock purchase warrant (the "Warrant") was issued to the reporting person in connection with the Advance pursuant to the Agreement. The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance.

F2 · derivative.expiration_date: The common stock purchase warrant (the "Warrant") was issued to the reporting person in connection with the Advance pursuant to the Agreement. The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance.

SEC source: 0001209191-19-006473 · doc4.xml · derivative · entry 1

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 5,000,000 shares

Expires not disclosed

F1 · kind: Represents an advance of $2,000,000 (the "Advance") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the "Agreement"). The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), at the Reporting Person's option, in whole or in part, at any time after issuance. The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events. The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable.

F1 · price: Represents an advance of $2,000,000 (the "Advance") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the "Agreement"). The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), at the Reporting Person's option, in whole or in part, at any time after issuance. The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events. The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable.

F1 · derivative.exercise_date: Represents an advance of $2,000,000 (the "Advance") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the "Agreement"). The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), at the Reporting Person's option, in whole or in part, at any time after issuance. The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events. The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable.

F1 · derivative.expiration_date: Represents an advance of $2,000,000 (the "Advance") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the "Agreement"). The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), at the Reporting Person's option, in whole or in part, at any time after issuance. The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events. The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable.

SEC source: 0001640334-22-000206 · form5.xml · derivative · entry 5

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,822

Underlying: Common Stock · 38,822 shares

Expires 2022-10-05

F1 · kind: Transactions were previously reported on various prior Form 4 filings; however, the entries were erroneously reported as non-derivative transactions in Common Stock and the resulting reported total ownership included the misclassified securities. The entry of these transactions is to correct this error and reflect the actual securities held by the Reporting Person.

F2 · derivative.expiration_date: The Multi Draw Credit Facility tranches have the option to convert into Common Stock upon maturity of the facilities.

SEC source: 0001640334-22-000206 · form5.xml · derivative · entry 3

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500,000

Underlying: Common Stock · 2,500,000 shares

Expires 2024-02-01

F1 · kind: Transactions were previously reported on various prior Form 4 filings; however, the entries were erroneously reported as non-derivative transactions in Common Stock and the resulting reported total ownership included the misclassified securities. The entry of these transactions is to correct this error and reflect the actual securities held by the Reporting Person.

SEC source: 0001209191-18-064353 · doc4.xml · nonDerivative · entry 1

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,153,917

F1 · kind: The shares were issued pursuant to the conversion of accrued and unpaid interest on a convertible note, which is no longer outstanding, at the conversion price of $.10 per share.

F1 · price: The shares were issued pursuant to the conversion of accrued and unpaid interest on a convertible note, which is no longer outstanding, at the conversion price of $.10 per share.

SEC source: 0001209191-18-056825 · doc4.xml · derivative · entry 2

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500,000

Underlying: Common Stock · 2,500,000 shares

Expires not disclosed

F2 · kind: The common stock purchase warrant (the "Warrant") was issued to the reporting person in connection with the Advance pursuant to the Agreement. The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance.

F3 · shares: Represents 50% of the number of shares issuable upon conversion of the Advance.

F2 · price: The common stock purchase warrant (the "Warrant") was issued to the reporting person in connection with the Advance pursuant to the Agreement. The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance.

F2 · derivative.exercise_date: The common stock purchase warrant (the "Warrant") was issued to the reporting person in connection with the Advance pursuant to the Agreement. The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance.

F2 · derivative.expiration_date: The common stock purchase warrant (the "Warrant") was issued to the reporting person in connection with the Advance pursuant to the Agreement. The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance.

SEC source: 0001209191-18-056825 · doc4.xml · derivative · entry 1

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 5,000,000 shares

Expires not disclosed

F1 · kind: Represents an advance of $2,000,000 (the "Advance") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the "Agreement"). The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), at the Reporting Person's option, in whole or in part, at any time after issuance. The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events. The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable.

F1 · price: Represents an advance of $2,000,000 (the "Advance") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the "Agreement"). The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), at the Reporting Person's option, in whole or in part, at any time after issuance. The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events. The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable.

F1 · derivative.exercise_date: Represents an advance of $2,000,000 (the "Advance") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the "Agreement"). The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), at the Reporting Person's option, in whole or in part, at any time after issuance. The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events. The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable.

F1 · derivative.expiration_date: Represents an advance of $2,000,000 (the "Advance") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the "Agreement"). The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), at the Reporting Person's option, in whole or in part, at any time after issuance. The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events. The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable.

SEC source: 0001640334-22-000206 · form5.xml · derivative · entry 2

Emerald Health Sciences Inc. · CIK 0001728413 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500,000

Underlying: Common Stock · 2,500,000 shares

Expires 2023-11-01

F1 · kind: Transactions were previously reported on various prior Form 4 filings; however, the entries were erroneously reported as non-derivative transactions in Common Stock and the resulting reported total ownership included the misclassified securities. The entry of these transactions is to correct this error and reflect the actual securities held by the Reporting Person.

SEC source: 0001209191-18-054866 · doc4.xml · derivative · entry 1

DHILLON PUNIT · CIK 0001425052 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2028-10-10

F1 · derivative.exercise_date: The option will vest in equal monthly installments over a one-year period commencing on the date of grant.

SEC source: 0001209191-18-054871 · doc4.xml · derivative · entry 1

DHILLON AVTAR S · CIK 0001260933 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000,000

Underlying: Common Stock · 1,000,000 shares

Expires 2028-10-10

F1 · derivative.exercise_date: The option will vest in equal monthly installments over a one-year period commencing on the date of grant.

SEC source: 0001209191-18-054867 · doc4.xml · derivative · entry 1

HEPPELL JAMES L · CIK 0001261140 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2028-10-10

F1 · derivative.exercise_date: The option will vest in equal monthly installments over a one-year period commencing on the date of grant.